{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-034217","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2026-05-12T21:21:12+00:00","discovered_at":"2026-05-12T21:22:00.317752+00:00","generated_at":"2026-05-12T21:22:09.699629+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"InfuSystem stockholders approve equity plan amendment raising share reserve to 7M","bullets":["Stockholders approved Third Amendment to 2021 Equity Plan, increasing authorized shares to 7,000,000, enabling further equity awards.","All seven Board nominees elected: Drs. Eichenbaum/Sviokla, Messrs. Gendron/Hundzinski/Shuda, Mses. Huss/Lachance.","Non-binding say-on-pay advisory vote passed: 11,915,842 for, 1,071,346 against, 83,491 abstain.","Ratification of Grant Thornton LLP as independent auditor for FY 2026 passed: 16,604,725 for, 613 against, 193,626 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-034217","json":"https://secwatch.observer/filing/0001628280-26-034217.json","markdown":"https://secwatch.observer/filing/0001628280-26-034217.md","text":"https://secwatch.observer/filing/0001628280-26-034217.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026034217/0001628280-26-034217-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026034217/infu-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:22:09.699629+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f3ccea3569d539777e5a221db185a8a1f477794","claim":"InfuSystem Holdings, Inc shareholders approved Advisory vote on executive compensation at the 2026-05-11 meeting.","evidence_excerpt":"Proposal No. 2: The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement as follows: For Against Abstain Broker Non-Votes 11,915,842 1,071,346 83,491 3,728,285","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026034217/0001628280-26-034217-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-11"}],"fact_type":"shareholder_vote"},{"claim_id":"b3608e215f5c8c5947023310cce183ec553fae7a","claim":"InfuSystem Holdings, Inc shareholders approved Amendment to the 2021 Equity Plan to increase authorized shares at the 2026-05-11 meeting.","evidence_excerpt":"Proposal No. 3: The Company's stockholders approved the amendment to the Company's 2021 Equity Plan to increase the number of authorized shares under the 2021 Equity Plan as follows: For Against Abstain Broker Non-Votes 10,770,778 2,199,707 100,194 3,728,285","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026034217/0001628280-26-034217-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-11"}],"fact_type":"shareholder_vote"},{"claim_id":"d84d5276815274323dfafe0ce41bab4705e31b68","claim":"InfuSystem Holdings, Inc shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm at the 2026-05-11 meeting.","evidence_excerpt":"Proposal No. 4: The Company's stockholders ratified the appointment of Grant Thornton LLP as the Company's registered independent accounting firm for the fiscal year ending December 31, 2026 as follows: For Against Abstain Broker Non-Votes 16,604,725 613 193,626 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026034217/0001628280-26-034217-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-11"}],"fact_type":"shareholder_vote"},{"claim_id":"d87aff65e03c88a6052841ea93f3bd54d8c64506","claim":"InfuSystem Holdings, Inc shareholders approved Election of Directors at the 2026-05-11 meeting.","evidence_excerpt":"Proposal No. 1: The Company's Board Nominees For Against Abstain Broker Non-Votes Kenneth D. Eichenbaum, MD, MSE 11,921,195 827,929 321,555 3,728,285 Paul A. Gendron 12,614,275 276,474 179,930 3,728,285 Ronald Hundzinksi 12,368,646 611,294 90,739 3,728,285 Beverly A. Huss 11,890,777 847,243 332,659 3,728,285 Carrie Lachance 12,920,694 65,053 84,932 3,728,285 Scott Shuda 11,914,592 834,532 321,555 3,728,285 Dr. John J. Sviokla 12,227,773 521,341 321,565 3,728,285 All seven of the Company's Board nominees (Drs Eichenbaum and Sviokla, Messrs. Gendron, Hundzkinski, and Shuda and Mses. Huss and Lachance) were elected to the Board.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1337013/000162828026034217/0001628280-26-034217-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-11"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}